Healio (12/12, Demko) reports, “Youth aged five to 24 years beginning antipsychotic therapy who received doses higher than 50 mg chlorpromazine equivalents had a 3.5-fold increased risk for unexpected death,” researchers concluded after comparing “the risk for unexpected death among children and youth who started treatment with antipsychotic vs. control medications using data from Medicaid enrollees aged five to 24 years in Tennessee who had no diagnosis of severe somatic illness, psychoses, Tourette syndrome or chronic tic disorder.” The findings were published online Dec. 12 in JAMA Psychiatry.
According to Psychiatric News (12/12), the author of an accompanying editorial wrote, “The ‘[r]esults…heighten the already increased caution about prescribing antipsychotics to children and adolescents.’” She added, “Concerns about excess deaths are likely to increase because the prevalence of some disorders for which antipsychotics are prescribed off-label (e.g., attention-deficit/hyperactivity disorder) and the number of prescriptions for indicated and off-label use are rising.” Medscape (12/12, Anderson, Subscription Publication) also covers the study.
Related Links:
— “Antipsychotic use may increase risk for unexpected death among youth, “Savannah Demko, Healio, December 12, 2018.